Medline outlines 2027 high single-digit net sales growth while launching a $1B share repurchase program (NASDAQ:MDLN)
· seekingalpha.com
Medline Q3 2026 earnings: sales guidance rises, EBITDA holds, buyback launches, and 2027 margin pressures emerge.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...